deltatrials
Completed PHASE2 NCT00328276

Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia

NMDA Enhancers in the Treatment of Schizophrenia

Sponsor: China Medical University Hospital

Conditions Psychoses Psychotic Disorders Schizophrenias Schizophrenic Disorders
Interventions Sarcosine
Updated 5 times since 2017 Last updated: May 18, 2006 Started: Dec 31, 2004 Completion: Dec 31, 2005

A PHASE2 clinical study on Psychoses and Psychotic Disorders, this trial is completed. The trial is conducted by China Medical University Hospital and has accumulated 5 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Change History

5 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE2

    First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • China Medical University Hospital
  • National Health Research Institutes, Taiwan
  • National Science and Technology Council, Taiwan
Data source: China Medical University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Taichung, Taiwan